博安生物(06955):BA1302 (CD228 ADC)完成中国Ia期临床研究

智通财经
Aug 14

智通财经APP讯,博安生物(06955)发布公告,公司自主研发的靶向CD228的创新抗体偶联药物(ADC)BA1302已完成中国I期临床研究单药剂量递增阶段(Ia期)。研究结果显示,BA1302在经多线治疗后疾病仍进展的多种晚期实体瘤患者中展现出良好的抗肿瘤活性,整体安全耐受性良好。

据公司所知,BA1302是目前全球唯一处于临床阶段的靶向CD228 ADC。CD228 靶点蛋白在黑色素瘤、乳腺癌、食管癌、鳞状非小细胞肺癌、头颈鳞癌、间皮瘤、结肠癌和胰腺癌等多种实体瘤中高表达,而在正常组织中表达较低,是理想的ADC靶点。在分子设计上,BA1302通过可裂解的亲水性连接子,将细胞毒素MMAE与CD228单抗经铰链区半胱氨酸偶联,通过抗体的精准靶向引导毒素到达肿瘤部位,发挥抗肿瘤效应的同时,降低毒副作用,提高治疗窗口。

公司认为,此次Ia期研究呈现出的初步疗效和安全性特征令人鼓舞,进一步增强了公司对CD228靶点价值及BA1302开发前景的信心。该药物在多个实体瘤中展现的单药活性与联合开发潜力,有望为肿瘤精准治疗开辟又一新路径。公司将加快推进BA1302的全球开发进程,探索该药物在更多适应症中的临床应用价值。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10